Tuesday, February 14, 2012

FDA panel backs new heart drug Multaq

(Reuters) UPDATED 2009-03-16
A panel of experts that advises the U.S. Food and Drug Administration (FDA) says that a new heart drug called Multaq should be approved for delaying symptoms of atrial fibrillation and reducing hospitalization among patients with this condition. After reviewing new data on the drug, the FDA panel found that Multaq appears useful in treating arrthymia and preventing atrial fibrillation hospitalizations. However, the panel said that Multaq should not be used by people with Class III and IV heart failure, and that the drug's maker should not be allowed to make claims that the medication decreases the risk of death.  Read full story >
See all Heart Disease News
Related: Multaq

People who read this also read...